The company have significantly improved the progress of a novel therapy for cardiac amyloidosis, leveraging the investigational drug. Preliminary trial data reveals promising benefits for those affected by the https://attr-cm258039.isblog.net/bridgebio-improves-attr-cm-management-with-attruby-59519735